Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 167833.48 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Consolidated Total Income of Rs 8633.98 Crore, down -5.66 % from last quarter Total Income of Rs 9151.73 Crore and up 4.18 % from last year same quarter Total Income of Rs 8287.17 Crore. Company reported net profit after tax of Rs 848.00 Crore in latest quarter.
Investment Rationale
The brokerage raises earnings estimate by 9%/8% for FY22E/FY23E, factoring in a) heightened demand due to COVID, steady growth in the Chronic segment, and recovery in the Sub-Chronic category in the DF segment; b) the benefit of an expanded field force in the DF segment; and c) improving traction in the global Specialty portfolio. Accordingly, it raises TP to INR830 on a 25x 12M forward earnings basis. It remains positive on SUNP on its superior execution in the global Specialty portfolio / Branded Generics and a robust ANDA pipeline
Promoter/FII Holdings
Promoters held 54.5 per cent stake in the company , FIIs held 11.7 per cent, DIIs 21.6 per cent and public and others 12.2 per cent.
(Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.)
